Lipofectamine MessengerMAX Reagent

• Rapid protein expression—enables rapid translation of mRNA into protein with no risk of genomic integration, to help accelerate experimental timelines
• Compatibility with many cell types—versatile for use with a wide range of cell lines, including neurons and primary cells
• Minimal cytotoxicity—maintains cell viability and health, making it an excellent choice for sensitive cells and long-term studies
• High-throughput compatibility—suitable for high-throughput screening to facilitate large-scale mRNA transfection studies
• More efficient genome editing—up to 10x more cleavage with CRISPR-Cas9 mRNA

Request a sample  Protocol library

Download application note on transfection of cryopreserved human and fresh rat hepatocytes using Lipofectamine MessengerMAX reagent

Lipofectamine MessengerMAX mRNA Transfection Reagent delivers amazing transfection efficiency in neurons and a broad-spectrum of primary cells, enabling improved application outcomes and more biologically relevant research. This reagent’s novel lipid nanoparticle technology is optimized to deliver a high amount of mRNA possible without the nuclear entry step that is required with DNA.

While DNA transfection is the most common method used to express a gene of interest, this process involves several steps, including DNA entry into the nucleus. The entry of DNA into the nucleus is often one of the most difficult transfection steps, especially in hard-to-transfect cells.

In contrast, mRNA transfection is simpler than DNA transfection as the mRNA transcript can be delivered directly into the cells and does not require nuclear entry (step 4, Figure 2) for expression. In addition, mRNA transfection is cell cycle independent and helps eliminate the risk of genomic integration.

Lipofectamine MessengerMAX Transfection Reagent, specifically designed for mRNA transfection, results in fast protein expression with homogeneity of expression among the transfected cells.

With Lipofectamine MessengerMAX Transfection Reagent, you can benefit from more efficient, reliable, and reproducible mRNA transfection (Figure 3).

Lipofectamine MessengerMAX Transfection Reagent increases the likelihood of cleavage and recombination when used with Invitrogen GeneArt CRISPR Nuclease mRNA, maximizing the efficiency of genetic modification and simplifying downstream processes (Figure 4).

1. Li H, Peng K, Yang K et al. (2022) Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics 12(14):6422–6436.
2. Shi L, Yang J, Nie Y et al. (2023) Hybrid mRNA nano vaccine potentiates antigenic peptide presentation and dendritic cell maturation for effective cancer vaccine therapy and enhances response to immune checkpoint blockade. Adv Healthc Mater 12(32):2301261.
3. Wesselhoeft RA, Kowalski PS, Parker-Hale FC et al. (2019) RNA circularization diminishes immunogenicity and can extend translation duration in vivo. Mol Cell 74(3):508–520.e4.
4. Jiang L, Park J-S, Yin L et al. (2020) Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat Commun 11:5339.
5. Zhang C, Delawary M, Huang P et al. (2021) IL-10 mRNA engineered MSCs demonstrate enhanced anti-inflammation in an acute GvHD model. Cells 10(11):3101.
6. Yu F, Gong D, Yan D et al. (2023) Enhanced adipose-derived stem cells with IGF-1-modified mRNA promote wound healing following corneal injury. Mol Ther 31(8):2454–2471.
7. Wu H, Peng Z, Xu Y (2022) Engineered adipose-derived stem cells with IGF-1-modified mRNA ameliorates osteoarthritis development. Stem Cell Res Ther 13:19.
8. Geng Y, Duan H, Xu L (2021) BMP-2 and VEGF-A modRNAs in collagen scaffold synergistically drive bone repair through osteogenic and angiogenic pathways.
9. Moradian H, Roch T, Anthofer L et al. (2022) Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages. Mol Ther Nucleic Acids 27:854–869.
10. Korchak JA, Delawary M, Huang P et al. (2022) Endothelial nitric oxide synthase-engineered mesenchymal stromal cells induce anti-inflammation in experimental immune models. Cytotherapy 24(3):262–271.
11. Billingsley MM, Singh N, Ravikumar P et al. (2020) Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett 20(3):1578–1589.
12. Hotz C, Wagenaar TR, Gieseke F et al. (2021) Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med 13(610):eabc7804.
13. Meertens L, Hafirassou ML, Couderc T et al. (2019) FHL1 is a major host factor for chikungunya virus infection. Nature 574:259–263.
14. De Alwis R, Gan ES, Chen S et al. (2021) A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Mol Ther 29(6):1970–1983.
15. Wu D, Huang R-T, Hamanaka RB et al. (2017) HIF-1α is required for disturbed flow-induced metabolic reprogramming in human and porcine vascular endothelium. eLife 6:e25217.
16. Singh RD, Hillestad ML, Livia C et al. (2019) M3RNA drives targeted gene delivery in acute myocardial infarction. Tissue Eng Part A 25(1–2):145–158.
17. Yamazaki K, Kubara K, Ishii S (2023) Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice. Mol Ther Nucleic Acids 33:210–226.
18. Jin Y, Shen Y, Su X (2020) Effective restoration of dystrophin expression in iPSCMdx-derived muscle progenitor cells using the CRISPR/Cas9 system and homology directed repair technology. Comput Struct Biotechnol J 18:765–773.